BS1801

BS1801 is a selenium-containing small molecule drug and an analog of ebselen. It acts as a specific inhibitor of thioredoxin reductase (TrxR), an enzyme involved in cellular redox regulation. By inhibiting TrxR, BS1801 disrupts redox homeostasis and exerts antifibrotic effects. The drug is being developed primarily for the treatment of fibrotic diseases such as pulmonary fibrosis (including idiopathic pulmonary fibrosis) and liver fibrosis/cirrhosis. Preclinical studies have also explored its potential in liver cancer and high-grade glioma. Pharmacokinetic studies indicate that BS1801 undergoes extensive metabolism via reduction, methylation, amide hydrolysis, and oxidation pathways; its main metabolite in humans is formed by reduction and Se-methylation. The compound is currently undergoing clinical evaluation with the highest phase reported as Phase 2 for pulmonary fibrosis[1][2][3][4].

Brand names

佛希灵

Other names

ebselen analogbutaselen